Biofrontera AG
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carci… Read more
Biofrontera AG (B8FK) - Net Assets
Latest net assets as of September 2025: €14.80 Million EUR
Based on the latest financial reports, Biofrontera AG (B8FK) has net assets worth €14.80 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€19.81 Million) and total liabilities (€5.01 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €14.80 Million |
| % of Total Assets | 74.72% |
| Annual Growth Rate | N/A |
| 5-Year Change | 155.67% |
| 10-Year Change | N/A |
| Growth Volatility | 257.59 |
Biofrontera AG - Net Assets Trend (2009–2024)
This chart illustrates how Biofrontera AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biofrontera AG (2009–2024)
The table below shows the annual net assets of Biofrontera AG from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €18.86 Million | -5.63% |
| 2023-12-31 | €19.98 Million | -1.75% |
| 2022-12-31 | €20.34 Million | -64.59% |
| 2021-12-31 | €57.43 Million | +678.66% |
| 2020-12-31 | €7.38 Million | -25.92% |
| 2019-12-31 | €9.96 Million | -39.14% |
| 2018-12-31 | €16.36 Million | +383.76% |
| 2017-12-31 | €3.38 Million | -78.66% |
| 2016-12-31 | €15.84 Million | +429.42% |
| 2015-12-31 | €-4.81 Million | -22800.77% |
| 2014-12-31 | €-21.00K | +99.54% |
| 2013-12-31 | €-4.55 Million | -11.07% |
| 2012-12-31 | €-4.09 Million | +67.33% |
| 2011-12-31 | €-12.53 Million | +2.82% |
| 2010-12-31 | €-12.89 Million | -24.35% |
| 2009-12-31 | €-10.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biofrontera AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6132637108.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €143.60 Million | 761.54% |
| Total Equity | €18.86 Million | 100.00% |
Biofrontera AG Competitors by Market Cap
The table below lists competitors of Biofrontera AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Baselode Energy Corp
OTCQB:BSENF
|
$3.86 Million |
|
R. S. Software (India) Limited
NSE:RSSOFTWARE
|
$3.86 Million |
|
Indian Card Clothing Company Limited
NSE:INDIANCARD
|
$3.86 Million |
|
Friday's Dog Holdings Inc.
PINK:FDOGF
|
$3.87 Million |
|
Lionheart Holdings Warrant
NASDAQ:CUBWW
|
$3.86 Million |
|
Alumexx N.V.
AS:ALX
|
$3.85 Million |
|
Resources & Energy Group Ltd
AU:REZ
|
$3.85 Million |
|
mVISE AG
XETRA:C1V
|
$3.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biofrontera AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 19,980,000 to 18,856,000, a change of -1,124,000 (-5.6%).
- Net loss of 4,350,000 reduced equity.
- New share issuances of 3,343,000 increased equity.
- Other comprehensive income decreased equity by 137,331,000.
- Other factors increased equity by 137,214,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-4.35 Million | -23.07% |
| Share Issuances | €3.34 Million | +17.73% |
| Other Comprehensive Income | €-137.33 Million | -728.31% |
| Other Changes | €137.21 Million | +727.69% |
| Total Change | €- | -5.63% |
Book Value vs Market Value Analysis
This analysis compares Biofrontera AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.87x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | €-1.46 | €2.69 | x |
| 2010-12-31 | €-1.11 | €2.69 | x |
| 2011-12-31 | €-0.89 | €2.69 | x |
| 2012-12-31 | €-0.14 | €2.69 | x |
| 2013-12-31 | €-0.16 | €2.69 | x |
| 2014-12-31 | €0.00 | €2.69 | x |
| 2015-12-31 | €-0.18 | €2.69 | x |
| 2016-12-31 | €0.50 | €2.69 | x |
| 2017-12-31 | €0.08 | €2.69 | x |
| 2018-12-31 | €0.35 | €2.69 | x |
| 2019-12-31 | €0.21 | €2.69 | x |
| 2020-12-31 | €0.13 | €2.69 | x |
| 2021-12-31 | €0.97 | €2.69 | x |
| 2022-12-31 | €0.35 | €2.69 | x |
| 2023-12-31 | €0.31 | €2.69 | x |
| 2024-12-31 | €3.10 | €2.69 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biofrontera AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -23.07%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -20.08%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 1.57x
- Recent ROE (-23.07%) is above the historical average (-64.01%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 0.00% | -1018.44% | 0.10x | 0.00x | €-2.39 Million |
| 2010 | 0.00% | -1886.52% | 0.16x | 0.00x | €-6.37 Million |
| 2011 | 0.00% | -901.21% | 0.09x | 0.00x | €-3.39 Million |
| 2012 | 0.00% | -120.01% | 0.38x | 0.00x | €-3.71 Million |
| 2013 | 0.00% | -259.00% | 0.32x | 0.00x | €-7.61 Million |
| 2014 | 0.00% | -346.33% | 0.22x | 0.00x | €-10.72 Million |
| 2015 | 0.00% | -270.75% | 0.44x | 0.00x | €-10.72 Million |
| 2016 | -66.78% | -172.57% | 0.26x | 1.51x | €-12.16 Million |
| 2017 | -476.25% | -133.90% | 0.61x | 5.87x | €-16.44 Million |
| 2018 | -54.28% | -42.06% | 0.54x | 2.39x | €-10.51 Million |
| 2019 | -73.91% | -23.53% | 0.54x | 5.86x | €-8.35 Million |
| 2020 | -176.58% | -42.92% | 0.54x | 7.65x | €-13.76 Million |
| 2021 | 65.73% | 131.13% | 0.38x | 1.33x | €32.00 Million |
| 2022 | -217.18% | -171.60% | 0.79x | 1.61x | €-46.20 Million |
| 2023 | -1.85% | -1.14% | 1.05x | 1.54x | €-2.37 Million |
| 2024 | -23.07% | -20.08% | 0.73x | 1.57x | €-6.24 Million |
Industry Comparison
This section compares Biofrontera AG's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $10,272,964,997
- Average return on equity (ROE) among peers: -102.80%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biofrontera AG (B8FK) | €14.80 Million | 0.00% | 0.34x | $3.86 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |